Biocon Limited has significantly improved its financial leverage, reducing its net debt to EBITDA ratio by approximately 1.6x. This improvement was driven by a systemic debt reduction plan and enhanced EBITDA performance. The company disclosed these developments in an investor presentation scheduled for analyst and institutional investor meets on June 02, 2026, and June 08, 2026.

The company completed an acquisition refinancing initiative that has strengthened its balance sheet and improved debt maturity profiles. Under the original debt profile as of September 2024, Biocon Biologics faced total debt obligations of $1,389 million, comprising acquisition debt, bilateral debt, and working capital. The refinancing has restructured these obligations into a new profile totaling $1,348 million as of March 2026, which includes an $800 million senior secured bond and new facility or bilateral debt.

Debt Maturity Schedule

The refinancing strategy has deferred major debt maturities, providing increased liquidity to address business needs. The new schedule shifts significant repayments to later fiscal years, allowing the company flexibility to invest cash from operations back into the business.

The original amortization schedule had required substantial repayments starting in FY25, whereas the new structure pushes the largest maturities toward FY28 and FY29. The total debt under the new arrangement stands at $1,348 million, compared to the previous $1,389 million.

Strategic Integration and Stake Acquisition

Biocon has advanced its business consolidation strategy, increasing its stake in Biocon Biologics to 99.2%. The Board of Directors has granted in-principle approval to acquire the remaining 0.8% stake. This integration combines the generics and biosimilar businesses to unlock value for patients, prescribers, customers, and shareholders.

The company reported that major investments in capacities and infrastructure are largely complete across the Biocon Group. This development positions the entity to meet demand requirements for the next five years or more. The consolidated business is positioned among global leaders in biosimilars and complex generics, with a portfolio addressing a total market opportunity of over $200 billion.

Financial Performance

The investor presentation highlighted robust financials for the Biocon Group, noting that new launches and business consolidation are expected to improve operating margins. The company has a vertically integrated operational model with research and development, manufacturing, and commercialization capabilities spanning 120+ countries. It holds 215+ cGMP approvals from 25+ regulators, including the US FDA and EMA.

Biocon Limited has revised the pricing structure for its preferential issue of equity shares, setting the floor price at ₹373.08 and the issue price at ₹376.41 per equity share. The company will issue 87,86,362 equity shares to shareholders of Biocon Biologics Limited (BBL) as part of a transaction to make BBL a wholly-owned subsidiary. The swap ratio has been fixed at 0.76159, meaning the company will issue 76.159 equity shares for every 100 equity shares of BBL held by the selling shareholders.

The revision follows advice from the National Stock Exchange of India Limited (NSE) and BSE Limited, which required the company to provide clarifications regarding the preferential issue. Consequently, the board approved amendments to the floor price, issue price, swap ratio, and the number of shares to be issued on May 28, 2026. The company issued a corrigendum to the postal ballot notice on May 28, 2026, and dispatched it electronically on May 29, 2026, to members registered as of May 01, 2026. Newspaper advertisements regarding the corrigendum were published in the Financial Express and Vijayavani on May 30, 2026.

Revised Pricing and Valuation

The floor price was determined based on the higher of the 90-day volume weighted average price (VWAP) of ₹373.08, the 10-day VWAP of ₹368.07, or the price determined by an independent registered valuer. Mr. Santosh Kumar Katla, an Independent Registered Valuer, certified the floor price at ₹373.08 per equity share in a report dated May 27, 2026. The final issue price of ₹376.41 includes a premium of ₹371.41 per equity share.

Shareholder Impact and Voting

The preferential issue will alter the company's shareholding pattern. While the promoter and promoter group holding will decrease slightly from 44.91% to 44.68%, the non-promoters' holding will increase from 55.09% to 55.32%. The total number of equity shares post-issue will rise to 1,62,96,94,135.

Votes already cast by members on the resolution prior to the receipt of this corrigendum remain valid. However, shareholders wishing to modify their votes in light of the new information may do so by emailing the scrutinizer at compliance@sreedharancs.com on or before 5:00 p.m. (IST) on June 07, 2026. The remote e-voting process commenced on May 09, 2026, and is scheduled to conclude on June 07, 2026. The corrigendum has been issued in compliance with Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.